Asian Pacific Journal of Cancer Prevention

Asian Pacific Journal of Cancer Prevention (아시아태평양암예방학회)
권호 표지
DOI QR코드

DOI QR Code

Impact of IL-2 and IL-2R SNPs on Proliferation and Tumor-killing Activity of Lymphokine-Activated Killer Cells from Healthy Chinese Blood Donors

  • Li, Yan (Molecular Oncology Department of Cancer Research Institution, The First Affiliated Hospital of China Medical University) ;
  • Meng, Fan-Dong (Molecular Oncology Department of Cancer Research Institution, The First Affiliated Hospital of China Medical University) ;
  • Tian, Xin (Molecular Oncology Department of Cancer Research Institution, The First Affiliated Hospital of China Medical University) ;
  • Sui, Cheng-Guang (Molecular Oncology Department of Cancer Research Institution, The First Affiliated Hospital of China Medical University) ;
  • Liu, Yun-Peng (Oncology, The First Affiliated Hospital of China Medical University) ;
  • Jiang, You-Hong (Molecular Oncology Department of Cancer Research Institution, The First Affiliated Hospital of China Medical University)
  • Published : 2014.10.11
Download PDF
⟨ Previous Next ⟩

Abstract

One of the goals of tumor immunotherapy is to generate immune cells with potent anti-tumor activity through in vitro techniques using peripheral blood collected from patients. However, cancer patients generally have poor immunological function. Thus using patient T cells, which have reduced in vitro proliferative capabilities and less tumor cell killing activity to generate lymphokine-activated killer (LAK) cells, fails to achieve optimal clinical efficacy. Interleukin-2 (IL-2) is a potent activating cytokine for both T cells and natural killer cells. Thus, this study aimed to identify optimal donors for allogeneic LAK cell immunotherapy based on single nucleotide polymorphisms (SNP) in the IL-2 and IL-2R genes. IL-2 and IL-2R SNPs were analyzed using HRM-PCR. LAK cells were derived from peripheral blood mononuclear cells by culturing with IL-2. The frequency and tumor-killing activity of LAK cells in each group were analyzed by flow cytometry and tumor cell killing assays, respectively. Regarding polymorphisms at IL-2-330 (rs2069762) T/G, LAK cells from GG donors had significantly greater proliferation, tumor-killing activity, and IFN-${\gamma}$ production than LAK cells from TT donors (P<0.05). Regarding polymorphisms at IL-2R rs2104286 A/G, LAK cell proliferation and tumor cell killing were significantly greater in LAK cells from AA donors than GG donors (P<0.05). These data suggest that either IL-2-330(rs2069762)T/G GG donors or IL-2R rs2104286 A/G AA donors are excellent candidates for allogeneic LAK cell immunotherapy.

Keywords

References

  1. Ainiding G, Kawano Y, Sato S, et al (2014). Interleukin 2 receptor $\alpha$ chain gene polymorphisms and risks of multiple sclerosis and neuromyelitis optica in southern Japanese. J Neurol Sci, 337, 147-50. https://doi.org/10.1016/j.jns.2013.11.037
  2. Archimbaud E, Bailly M, Dore JF (1991). Inducibility of lymphokine activated killer (LAK) cells in patients with acute myelogenous leukaemia in complete remission and its clinical relevance. Br J Haematol, 77, 328-34. https://doi.org/10.1111/j.1365-2141.1991.tb08579.x
  3. Bei CH, Bai H, Yu HP, et al (2014). Combined Effects of Six Cytokine Gene Polymorphisms and SNP-SNP Interactions on Hepatocellular Carcinoma Risk in Southern Guangxi, China. Asian Pac J Cancer Prev, 15, 6961-7. https://doi.org/10.7314/APJCP.2014.15.16.6961
  4. Brady J, Carotta S, Thong RP, et al (2010). The interactions of multiple cytokines control NK cell maturation. J Immunol, 185, 6679-88. https://doi.org/10.4049/jimmunol.0903354
  5. Buckner JH (2010). Mechanisms of impaired regulation by CD4+CD25+FOXP3+ regulatory T cells in human autoimmune diseases. Nat Rev Immunol, 10, 849-59. https://doi.org/10.1038/nri2889
  6. Carr EJ, Clatworthy MR, Lowe CE, et al (2009). Contrasting genetic association of IL2RA with SLE and ANCAassociated vasculitis. BMC Med Genet, 10, 22.
  7. Cui Zhou, Song-Song Jiang, Cui-Yan Wang, et al (2014). Different immunology mechanisms of Phellinus igniarius in inhibiting growth of liver cancer and melanoma cells. Asian Pac J Cancer Prev, 15, 3659-65. https://doi.org/10.7314/APJCP.2014.15.8.3659
  8. Chan CJ, Andrews DM, McLaughlin NM, et al (2010). DNAM-1/CD155 nteractionspromote cytokine and NK cell-mediated suppression of poorly immunogenicmelanoma metastases. J Immunol, 184, 902-11. https://doi.org/10.4049/jimmunol.0903225
  9. Dendrou CA, Plagnol V, Fung E, et al (2009). Cell-specific protein phenotypes for the autoimmune locus IL2RA using a genotype-selectable human bioresource. Nat Genet , 41, 1011-5. https://doi.org/10.1038/ng.434
  10. Erhan Aysan, Omer Faruk Bayrak, Esra Aydemir, et al (2013). cancer preventive effects of whole cell type immunization against mice Ehrlich tumors. Asian Pac J Cancer Prev, 14, 3515-9. https://doi.org/10.7314/APJCP.2013.14.6.3515
  11. Feriazzo G, Moretta L (2014). Dendritic cell editing by natural killer cells. Crit Rev Oncog, 19, 67-75. https://doi.org/10.1615/CritRevOncog.2014010827
  12. Grimm EA, Mazumder A, Zhang HZ, et al (1982). Lymphokineactivated killer cell phenomenon.Lysis of natural killerresistant fresh solid tumor cells by Interleukin 2-activated autologous human peripheral blood lymphocytes. J Exp Med, 155, 1823-41. https://doi.org/10.1084/jem.155.6.1823
  13. Hoffmann SC, Stanley EM, Darrin Cox E, et al (2001). Association of cytokine polymorphic inheritance and in vitro cytokine production in anti-CD3/CD28- stimulated peripheral blood lymphocytes.Transplantation, 72, 1444-50. https://doi.org/10.1097/00007890-200110270-00019
  14. John S, Turner D, Donn R, et al (1998). Two novel biallelic polymorphisms in the IL-2 gene. Eur J Immunogenet, 25, 419-20. https://doi.org/10.1046/j.1365-2370.1998.00139.x
  15. Kelly JM, Darcy PK, Markby JL, et al (2002). Induction of tumor-specific T cell memory by NK cell-mediated tumor rejection. Nat Immunol, 3, 83-90.
  16. Kimura H, Iizasa T, Ishikawa A, Shingyouji M.Yoshino M, Kimura KM, et al (2008). Prospective phase II study of postsurgical adjuvant chemo-immunotherapy using autologous dendritic cells and activated killer cells from tissue culture of tumor-draining lymph nodes in primary lung cancer patients. Anticancer Res, 28, 1229-38.
  17. Koh CY, Blazar BR, George T, et al (2001). Augmentation of antitumor effects by NK cell inhibitory receptor blockade in vitro and in vivo. Blood, 97, 3132-7. https://doi.org/10.1182/blood.V97.10.3132
  18. Imai K, Matsuyama S, Miyake S, et al (2000). Natural cytotoxic activity of peripheral-blood lymphocytes and cancer incidence:An 11-year follow-up study of a general population. Lancet, 356, 1795-9. https://doi.org/10.1016/S0140-6736(00)03231-1
  19. Lanier LL, Sun JC (2009). Natural killer cells remember:An evolutionary bridge between innate and adaptive immunity? Eur J Immunol, 39, 2059-64. https://doi.org/10.1002/eji.200939435
  20. Lomonaco E, Tremante E, Cerboni C, et al (2011). Human leukocyteantigen E Contributes to protect tumor cells from lysis by natural killercells. Neoplasia, 13, 822-30. https://doi.org/10.1593/neo.101684
  21. Lowe CE, Cooper JD, Brusko T, et al (2007). Large-scale genetic fine mapping and genotype-phenotype associations implicate polymorphism in the IL2RA region in type 1 diabetes. Nat Genet, 39, 1074-82. https://doi.org/10.1038/ng2102
  22. Malek TR (2003). The main function of IL-2 is to promote the development of T regulatory cells. J Leukoc Biol, 74, 961-5. https://doi.org/10.1189/jlb.0603272
  23. Maier LM, Lowe CE, Cooper J, et al (2009). IL-2RA genetic heterogeneity in multiple sclerosis and type 1 diabetes susceptibility and soluble interleukin-2 receptor production. PLoS Genet, 5, 1000322. https://doi.org/10.1371/journal.pgen.1000322
  24. Ruggeri L, Mancusi A, Burchielli E, et al (2007). Natural killer cell alloreactivity in a allogeneic hematopoietic transplantation. Curr Opin Oncol, 19, 142-7. https://doi.org/10.1097/CCO.0b013e3280148a1a
  25. Shubina IZ, Demidov LV, Chikileva IO, et al (2008). LAK immunotherapy in clinical studies. Atlas Effectors of Anti-Tumor Immunity. Springer, 101-10.
  26. Smyth DJ, Plagnol V, Walker NM, et al (2008). Shared and distinct genetic variants in type 1 diabetes and celiac disease. N Engl J Med, 359, 2767-77. https://doi.org/10.1056/NEJMoa0807917
  27. Srivastava S, Lundqvist A, Childs RW (2008). Natural killer cell immunotherapy for cancer:a new hope. Cytotherapy, 10, 775-83. https://doi.org/10.1080/14653240802648181
  28. Togawa S, Joh T, Itoh M, et al (2005). Interleukin-2 gene polymorphisms associated with increased risk of gastric atrophy from Helicobacter pylori infection. Helicobacter, 10, 172-8. https://doi.org/10.1111/j.1523-5378.2005.00308.x
  29. Waldmann TA (2006). The biology of interleukin-2 and interleukin-15:Implications for cancer therapy and vaccinedesign. Nat Rev Immunol, 6, 595-601. https://doi.org/10.1038/nri1901
  30. Wang R, Ciardelli TL, Russell JH (1997). Partial signaling by cytokines:Cytokine regulation of cell cycle and Fasdependent, activation-induced death in CD4+subsets. Cell Immunol, 182, 152-60. https://doi.org/10.1006/cimm.1997.1220
  31. Wang X, Ricker M, Garcia KC (2005). Structure of the quaternary complex of interleukin-2 with its alpha, beta, and gamma receptors. Science, 310, 1159. https://doi.org/10.1126/science.1117893
  32. Waldmann H (2006). Immunology:protection and privilege. Nature, 442, 987-8. https://doi.org/10.1038/nature05165

Cited by

  1. Antitumor effect of a polysaccharide isolated from Phellinus pullus as an immunostimulant vol.4, pp.3, 2016, https://doi.org/10.3892/br.2016.587
  2. Efficacy of Early Enteral Immunonutrition on Immune Function and Clinical Outcome for Postoperative Patients With Gastrointestinal Cancer pp.1941-2444, 2017, https://doi.org/10.1177/0148607117715439